Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Natera, Inc. | Director | Common Stock | 1.55M | $184M | $118.81 | Oct 25, 2024 | by Sofinnova Venture Partners IX, L.P. |
Y-mAbs Therapeutics, Inc. | Director | Common Stock | 2.19M | $26.3M | $12.00 | Jun 11, 2024 | Indirect |
ArriVent Biopharma, Inc. | Director | Common Stock | 1.7M | $6.19M | $3.65 | Jan 30, 2024 | Sofinnova Venture Partners XI, L.P. |
Natera, Inc. | Director | Common Stock | 46K | $5.47M | $118.81 | Oct 25, 2024 | Direct |
Y-mAbs Therapeutics, Inc. | Director | Common Stock | 31.6K | $379K | $12.00 | Jun 11, 2024 | Direct |
Karuna Therapeutics, Inc. | Director | Common Stock | 0 | $0 | $330.00 | Mar 18, 2024 | By Sofinnova Management X, L.P. |
Karuna Therapeutics, Inc. | Director | Common Stock | 0 | $0 | $330.00 | Mar 18, 2024 | By Sofinnova Synergy Master Fund, LP |
Karuna Therapeutics, Inc. | Director | Common Stock | 0 | $0 | $330.00 | Mar 18, 2024 | By Sofinnova Venture Partners X, LP |
Karuna Therapeutics, Inc. | Director | Common Stock | 0 | $0 | $330.00 | Mar 18, 2024 | Direct |
Karuna Therapeutics, Inc. | Director | Option (right to buy) | 0 | $0 | $92.30 | Mar 18, 2024 | Direct |
BioAge Labs, Inc. | Director | Common Stock | 2.23M | Sep 27, 2024 | Sofinnova Venture Partners XI, L.P. | ||
Rapport Therapeutics, Inc. | Director | Common Stock | 1.86M | Jul 1, 2024 | By Sofinnova Venture Partners XI, L.P. | ||
Rapport Therapeutics, Inc. | Director | Common Stock | 40.9K | Jul 1, 2024 | By Crestline Summit Master, SPC - PEAK SP | ||
Rapport Therapeutics, Inc. | Director | Common Stock | 39.7K | Jul 1, 2024 | By CRESTLINE SUMMIT PINNACLE MASTER, L.P. | ||
Rapport Therapeutics, Inc. | Director | Common Stock | 33.1K | Jul 1, 2024 | By Crestline Summit Master, SPC - CRESTLINE SUMMIT APEX SP | ||
Coherus BioSciences, Inc. | Director | Stock Option (Right to Buy) | 27K | Jan 7, 2022 | Direct | ||
BioAge Labs, Inc. | Director | Common Stock | 26.5K | Sep 27, 2024 | CRESTLINE SUMMIT PINNACLE MASTER, L.P. | ||
Bolt Biotherapeutics, Inc. | Director | Stock Option (Right to Buy) | 22K | Jun 12, 2024 | Direct | ||
BioAge Labs, Inc. | Director | Common Stock | 21.8K | Sep 27, 2024 | Crestline Summit Master, SPC - PEAK SP | ||
Rapport Therapeutics, Inc. | Director | Common Stock | 18.6K | Jul 1, 2024 | By Sofinnova Synergy Master Fund LP | ||
BioAge Labs, Inc. | Director | Common Stock | 18.4K | Sep 27, 2024 | CRESTLINE SUMMIT MASTER, SPC - CRESTLINE SUMMIT APEX SP | ||
BioAge Labs, Inc. | Director | Stock Option (Right to Buy) | 15K | Sep 25, 2024 | Direct | ||
Y-mAbs Therapeutics, Inc. | Director | Employee Stock Option (right to buy) | 14.5K | Jun 11, 2024 | Direct | ||
BioAge Labs, Inc. | Director | Common Stock | 11.1K | Sep 27, 2024 | Sofinnova Synergy Master Fund LP | ||
ArriVent Biopharma, Inc. | Director | Series B Preferred Stock | 0 | Jan 30, 2024 | Sofinnova Venture Partners XI, L.P. | ||
BioAge Labs, Inc. | Director | Series D Preferred Stock | 0 | Sep 27, 2024 | Sofinnova Venture Partners XI, L.P. | ||
CinCor Pharma, Inc. | Director, 10%+ Owner | Common Stock | 0 | $28.75 | Nov 28, 2022 | By Sofinnova Synergy Master Fund, LP | |
CinCor Pharma, Inc. | Director, 10%+ Owner | Common Stock | 0 | $28.75 | Feb 24, 2023 | By Sofinnova Venture Partners X, L.P. | |
CinCor Pharma, Inc. | Director, 10%+ Owner | Common Stock | 0 | $28.75 | Feb 24, 2023 | Direct | |
Rapport Therapeutics, Inc. | Director | Series B Preferred Stock | 0 | Jun 10, 2024 | By Sofinnova Venture Partners XI, L.P. |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
NTRA | Natera, Inc. | Oct 25, 2024 | 1 | $0 | 4 | Oct 29, 2024 | Director |
BIOA | BioAge Labs, Inc. | Sep 25, 2024 | 8 | $12M | 4 | Sep 27, 2024 | Director |
BIOA | BioAge Labs, Inc. | Sep 25, 2024 | 0 | $0 | 3 | Sep 25, 2024 | Director |
NTRA | Natera, Inc. | Jul 26, 2024 | 1 | $0 | 4 | Jul 30, 2024 | Director |
RAPP | Rapport Therapeutics, Inc. | Jul 1, 2024 | 12 | $1.08M | 4 | Jul 3, 2024 | Director |
NTRA | Natera, Inc. | Jun 28, 2024 | 1 | $0 | 4 | Jul 2, 2024 | Director |
BOLT | Bolt Biotherapeutics, Inc. | Jun 12, 2024 | 1 | $0 | 4 | Jun 14, 2024 | Director |
YMAB | Y-mAbs Therapeutics, Inc. | Jun 11, 2024 | 2 | $0 | 4 | Jun 13, 2024 | Director |
RAPP | Rapport Therapeutics, Inc. | Jun 10, 2024 | 7 | $9.5M | 4 | Jun 10, 2024 | Director |
RAPP | Rapport Therapeutics, Inc. | Jun 6, 2024 | 0 | $0 | 3 | Jun 6, 2024 | Director |
NTRA | Natera, Inc. | Apr 26, 2024 | 1 | $0 | 4 | Apr 30, 2024 | Director |
KRTX | Karuna Therapeutics, Inc. | Mar 18, 2024 | 9 | -$473M | 4 | Mar 18, 2024 | Director |
AVBP | ArriVent Biopharma, Inc. | Jan 30, 2024 | 3 | $8M | 4 | Jan 31, 2024 | Director |
NTRA | Natera, Inc. | Jan 26, 2024 | 1 | $16.8K | 4 | Jan 30, 2024 | Director |
AVBP | ArriVent Biopharma, Inc. | Jan 25, 2024 | 0 | $0 | 3 | Jan 25, 2024 | Director |
NTRA | Natera, Inc. | Dec 13, 2023 | 1 | -$37.8M | 4 | Dec 22, 2023 | Director |
NTRA | Natera, Inc. | Oct 27, 2023 | 1 | $16.9K | 4 | Oct 31, 2023 | Director |
NTRA | Natera, Inc. | Jul 28, 2023 | 1 | $15.9K | 4 | Aug 1, 2023 | Director |
NTRA | Natera, Inc. | Jun 30, 2023 | 2 | $0 | 4 | Jul 5, 2023 | Director |
KRTX | Karuna Therapeutics, Inc. | Jun 20, 2023 | 2 | $0 | 4 | Jun 22, 2023 | Director |
KRTX | Karuna Therapeutics, Inc. | Jun 14, 2023 | 2 | $0 | 4 | Jun 20, 2023 | Director |
BOLT | Bolt Biotherapeutics, Inc. | Jun 12, 2023 | 1 | $0 | 4 | Jun 14, 2023 | Director |
YMAB | Y-mAbs Therapeutics, Inc. | Jun 8, 2023 | 2 | $0 | 4 | Jun 9, 2023 | Director |
NTRA | Natera, Inc. | May 25, 2023 | 2 | $0 | 4 | May 30, 2023 | Director |
NTRA | Natera, Inc. | Apr 14, 2023 | 1 | $15.6K | 4 | Apr 18, 2023 | Director |
NTRA | Natera, Inc. | Jan 13, 2023 | 1 | $15.6K | 4 | Jan 18, 2023 | Director |
KRTX | Karuna Therapeutics, Inc. | Jan 12, 2023 | 3 | -$1.2M | 4 | Jan 17, 2023 | Director |
CINC | CinCor Pharma, Inc. | Nov 28, 2022 | 4 | -$85.9K | 4 | Feb 27, 2023 | Director, 10%+ Owner |
NTRA | Natera, Inc. | Nov 16, 2022 | 1 | -$90.5K | 4 | Jan 18, 2023 | Director |
NTRA | Natera, Inc. | Oct 14, 2022 | 1 | $15.6K | 4 | Oct 18, 2022 | Director |
CINC | CinCor Pharma, Inc. | Aug 11, 2022 | 2 | $15.2M | 4 | Aug 15, 2022 | Director, 10%+ Owner |
KRTX | Karuna Therapeutics, Inc. | Aug 5, 2022 | 2 | $520K | 4 | Aug 8, 2022 | Director |
CINC | CinCor Pharma, Inc. | Aug 5, 2022 | 2 | $400K | 4 | Aug 8, 2022 | Director, 10%+ Owner |
YMAB | Y-mAbs Therapeutics, Inc. | Jul 15, 2022 | 1 | $0 | 4 | Jul 19, 2022 | Director |
NTRA | Natera, Inc. | Jul 8, 2022 | 1 | $0 | 4/A | Sep 2, 2022 | Director |
KRTX | Karuna Therapeutics, Inc. | Jun 29, 2022 | 6 | $14.7M | 4 | Jul 1, 2022 | Director |
KRTX | Karuna Therapeutics, Inc. | Jun 15, 2022 | 1 | $0 | 4 | Jun 16, 2022 | Director |
BOLT | Bolt Biotherapeutics, Inc. | Jun 10, 2022 | 1 | $0 | 4 | Jun 10, 2022 | Director |
NTRA | Natera, Inc. | May 27, 2022 | 2 | $0 | 4 | Jun 1, 2022 | Director |
NTRA | Natera, Inc. | May 25, 2022 | 2 | $0 | 4 | May 27, 2022 | Director |
KRTX | Karuna Therapeutics, Inc. | Apr 1, 2022 | 1 | $6.08K | 4 | Apr 14, 2022 | Director |
BOLT | Bolt Biotherapeutics, Inc. | Mar 24, 2022 | 1 | $0 | 4 | Mar 28, 2022 | Director |
CINC | CinCor Pharma, Inc. | Jan 11, 2022 | 4 | $5.2M | 4 | Jan 13, 2022 | Director, 10%+ Owner |
CHRS | Coherus BioSciences, Inc. | Jan 7, 2022 | 1 | $0 | 4/A | Feb 11, 2022 | Director |
CINC | CinCor Pharma, Inc. | Jan 6, 2022 | 0 | $0 | 3 | Jan 6, 2022 | Director, 10%+ Owner |
CHRS | Coherus BioSciences, Inc. | Sep 27, 2021 | 3 | -$7.25M | 4 | Sep 29, 2021 | Director |
NTRA | Natera, Inc. | Jul 22, 2021 | 1 | $271K | 4 | Jul 26, 2021 | Director |
KRTX | Karuna Therapeutics, Inc. | Jul 2, 2021 | 1 | $74.9K | 4 | Jul 7, 2021 | Director |
KRTX | Karuna Therapeutics, Inc. | Jun 16, 2021 | 1 | $0 | 4 | Jun 23, 2021 | Director |
NTRA | Natera, Inc. | May 28, 2021 | 4 | $0 | 4 | Jun 2, 2021 | Director |
YMAB | Y-mAbs Therapeutics, Inc. | Jun 10, 2020 | 1 | $0 | 4 | Jun 14, 2021 | Director |